Announcement

Collapse
No announcement yet.

Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial

    Anticancer Res. 2020 Nov;40(11):6473-6484. doi: 10.21873/anticanres.14669.
    Authors
    Koichi Mitsuya 1 2 , Yasuto Akiyama 3 2 , Akira Iizuka 1 , Haruo Miyata 1 , Shoichi Deguchi 2 , Nakamasa Hayashi 2 , Chie Maeda 1 , Ryota Kondou 1 , Akari Kanematsu 1 , Kyoko Watanabe 1 , Tadashi Ashizawa 1 , Yoshiaki Abe 4 , Ichiro Ito 5 , Takuma Oishi 6 , Takashi Sugino 6 , Yoko Nakasu 2 , Ken Yamaguchi 7
    Affiliations

    1 Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
    2 Division of Neurosurgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
    3 Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka Cancer Center Hospital, Shizuoka, Japan [email protected].
    4 Division of Blood Transfusion,, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
    5 Division of Pathology, Nagano Red Cross Hospital, Nagano, Japan.
    6 Division of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
    7 Office of the President, Shizuoka Cancer Center Hospital, Shizuoka, Japan.

    PMID: 33109586
    DOI: 10.21873/anticanres.14669

    Abstract

    Background/aim: Glioblastoma multiforme (GBM) is an intractable tumor that has a very poor prognosis despite intensive treatment with temozolomide plus radiotherapy.

    Patients and methods: Sixteen newly diagnosed patients with high-grade gliomas were enrolled in a phase II study of the α-type-1 DC vaccine. Briefly, DCs obtained from the culture of enriched monocytes in the presence of a cytokine cocktail, were pulsed with a cocktail of 5 synthetic peptides and cryopreserved until injection into patients.

    Results: The amount of IL-12 produced by activated DCs was higher than that previously reported. Among 15 evaluable patients, 10 showed positive CTL responses to any peptides in an ELISPOT assay. After 6 years of observation, five patients were still alive, and two of these patients were relapse-free. Moreover, a significant survival-prolonging effect was verified in DC-treated glioma patients.

    Conclusion: Peptide-cocktail-pulsed α-type-1 DC vaccines have a potential therapeutic effect on survival when used in combination with the standard regimen, which is partly based on IL-12-IFN-γ-mediated T-cell activation.

    Keywords: Activated dendritic cell; HLA-A24; high-grade glioma; immunotherapy; phase II trial.

    Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

  • #2
    Al's Comment:

    This is a small study but had remarkable results.1/3 of Glioblastoma patients lived at least 6 years.

    Comment

    Working...
    X